Determination of EGFR and KRAS mutational status in Greek nonsmallcell lung cancer patients

Author：

E-ISSN： 1792-1082|10|4|2176-2184

ISSN： 1792-1074

Source： Oncology Letters, Vol.10, Iss.4, 2015-01, pp. : 2176-2184

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi Nakagawa Kazuhiko

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

By Cheng Liang Zhang Shaobo Alexander Riley Yao Yongxue MacLennan Gregory T Pan Chong-xian Huang Jiaoti Wang Mingsheng Montironi Rodolfo Lopez-Beltran Antonio

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 519-541

Future Medicine

Access to resources Recommend Favorite

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1045-1052

Spandidos Publications

Access to resources Recommend Favorite

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

Oncology Reports, Vol. 30, Iss. 2, 2013-01 ,pp. : 623-636

Spandidos Publications

Access to resources Recommend Favorite

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer

By Metro Giulio Chiari Rita Baldi Alice De Angelis Verena Minotti Vincenzo Crinò Lucio

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 167-177

Future Medicine

Access to resources Recommend Favorite